VANCOUVER, BC / ACCESS Newswire / April 24, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly owned subsidiary, Inka Health Corp. ("Inka Health"), signed a new analytical work contract[1] with AstraZeneca Canada ("AstraZeneca") on March 20, 2025 to support the next phase of real-world evidence (RWE) research and scientific dissemination. The Company perceives this renewed engagement as a meaningful signal of confidence in Inka Health's capacity to support drug evaluation, submission strategies, and evidence planning within Canada's regulatory framework.
As part of the new scope of work commissioned by AstraZeneca, Inka Health will lead the development of a peer-reviewed scientific manuscript exploring the evolving role of international RWE in submissions to Canada's Drug Agency (CDA). This project will involve expanded analysis and synthesis of insights to inform how data generated outside Canada is leveraged within the Canadian regulatory environment-a growing area of interest in oncology and broader pharmaceutical development.
"This next phase of work for AstraZeneca gives us a valuable opportunity to examine how international real-world data is being operationalized in regulatory submissions, not just conceptually, but in real-world application. It builds directly on the analytical foundation we've developed through our previous work, and allows us to explore how evidence generated outside of Canada can be responsibly and effectively translated into local regulatory and health technology assessment processes," stated Paul Arora, CEO of Inka Health.
This expanded engagement builds on previously completed analytical work delivered under the AZ Services Agreement, deepening a strategic collaboration that has demonstrated Inka Health's leadership in causal analytics and evidence translation in regulatory and market access contexts. The prior phase of the analytical work focused on methodologies to address bias and generalizability challenges in non-local RWE and included a comprehensive review of RWE use in Canadian regulatory submissions[2]. Findings from this earlier work were accepted for presentation at ISPOR 2025 (from May 11-15, 2025), the leading global conference for health economics and outcomes research (See Company press release April 3, 2025).
About Inka Health
Inka Health is an AI-driven analytics company revolutionizing oncology research and drug development through advanced causal AI. Its proprietary platform, SynoGraph, leverages AI-powered causal inference to identify which cancer patients are most likely to respond to specific treatments, advancing precision medicine. By integrating diverse multimodal medical data-including genomics, transcriptomics, and proteomics-SynoGraph uncovers hidden insights that can optimize treatment decisions and clinical trial design. With this cutting-edge technology, Inka Health helps pharmaceutical companies accelerate drug development, reduce trial failures, and bring life-saving therapies to market faster.
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to prevent and cure cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours, setting new standards in cancer treatment. Onco's commitment to excellence and innovation drives it to develop advanced therapies that improve patient outcomes and offer hope in the fight against cancer.
ON BEHALF OF ONCO-INNOVATIONS LIMITED,
"Thomas O'Shaughnessy"
Chief Executive Officer
For more information, please contact:
Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
investors@oncoinnovations.com
The CSE and Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release.
Forward-Looking Statements Caution. This news release contains forward-looking statements relating to the further development, potential commercialization and benefits of the Company's technologies, including Synograph, as well as the abilities and prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to further develop, prove out or commercialize the Company's technologies, the failure to fulfill contractual requirements, the failure to receive regulatory approval in respect of the technologies, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
[1] Inka Health entered into the new analytical work contract with AstraZeneca Canada on March 20, 2025, for a prescribed fee. The services under this engagement are scheduled for completion by October 31, 2025.
[2] ISPOR. (2025). A Comprehensive Review of Real-World Evidence (RWE) Use in Submissions to Canada's Drug Agency (CDA). ISPOR 2025 Presentations Database.
SOURCE: Onco-Innovations Limited
View the original press release on ACCESS Newswire
